Selenium Supplements May Slow Progression of HIV

But the mineral should only be used as an adjunct to proven drug therapy, experts say

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Abscess • Actinomycosis • Acute Myeloid Leukemia (Adult) • AIDS and HIV Infection More... Related Healthscout Videos Early Babies: How Soon is Too Soon? Vaccination Education Brainy Baby Fighting Flu (LF) More... Related Animations • Erectile Dysfunction • Menopause More... Related Drug Information • Abilify • Augmentin • Bactroban Cream • Bactroban Ointment More... Related News Articles • Focusing on School Could Prevent Teen Pregnancies • Milk Supplement Saves Preemies • Quick, Safe, Accurate Endometriosis Diagnosis • Study: Breastfeeding Reduces Breast Cancer Risk More...

MONDAY, Jan. 22 (HealthDay News) -- Supplements of the mineral selenium appear to reduce or slow the progression of HIV, University of Miami researchers report.

Deficiencies in selenium have been noted in HIV-positive patients, and evidence suggests that supplements of the nutrient can improve immune system function, the researchers report in the Jan. 22 issue of the Archives of Internal Medicine.

Text Continues Below

---

"Those individuals who were treated with selenium displayed no further progression of HIV disease, whereas those who were on placebo evidenced a continued increase in HIV viral load," said lead researcher and professor of psychology Barry E. Hurwitz.

Another expert said the importance of the findings should not be overstated, however.

"That a cheap micronutrient might help blunt the short-term progression of HIV infection is wonderful news and can offer an intervention for persons in care settings who are not yet eligible for, or do not yet have access to, potent antiretroviral therapies," said Dr. Sten H. Vermund, the Amos Christie Chair and director of the Vanderbilt Institute for Global Health at Vanderbilt University in Nashville, Tenn.

However, he stressed that "by no means is selenium a treatment alternative, as the authors state, since the magnitude of benefit pales in comparison to that of antiretrovirals." Vermund was not involved in the study.

In the study, Hurwitz and colleagues randomly assigned 262 patients infected with HIV to 200 micrograms of selenium per day or placebo. Over the first nine months of the trial, the researchers monitored the patients' CD4 immune T-cell count (a measure of immune system health) and HIV viral load (the number of copies of the HIV virus in the blood).

They found that, among the 174 patients who completed the trial, those receiving the selenium supplement had reductions in their HIV viral load and increases in their CD4 count compared with those taking placebo. Among those taking placebo, viral load continued to increase, and CD4 counts continued to decline, Hurwitz said.

Page:  1 | 2 | 3 | Next >>